Post-HCT cardiovascular risk factors, anthracycline exposure, and risk of CHF*
| . | Hypertension OR (95% CI) . | Diabetes OR (95% CI) . | Dyslipidemia OR (95% CI) . | Thyroid OR (95% CI) . |
|---|---|---|---|---|
| No CV risk factor; no HD-anthracycline (referent group) | 1.0 | 1.0 | 1.0 | 1.0 |
| Model 1: CV risk factor alone; no HD anthracycline | 3.5 (0.88-14.01) | 6.2 (0.86-43.82) | 2.7 (0.56-13.40) | 0.7 (0.2-4.6) |
| Model 2: No CV risk factor; HD anthracycline alone | 4.8 (2.04-11.41) | 5.1 (2.34-10.93) | 5.6 (2.55-12.44) | 4.4 (2.09-9.32) |
| Model 3: CV risk factor and HD anthracycline | 35.3 (8.30-150.18) | 26.8 (4.34-165.2) | 5.4 (1.53-18.95) | 3.3 (0.82-13.22) |
| . | Hypertension OR (95% CI) . | Diabetes OR (95% CI) . | Dyslipidemia OR (95% CI) . | Thyroid OR (95% CI) . |
|---|---|---|---|---|
| No CV risk factor; no HD-anthracycline (referent group) | 1.0 | 1.0 | 1.0 | 1.0 |
| Model 1: CV risk factor alone; no HD anthracycline | 3.5 (0.88-14.01) | 6.2 (0.86-43.82) | 2.7 (0.56-13.40) | 0.7 (0.2-4.6) |
| Model 2: No CV risk factor; HD anthracycline alone | 4.8 (2.04-11.41) | 5.1 (2.34-10.93) | 5.6 (2.55-12.44) | 4.4 (2.09-9.32) |
| Model 3: CV risk factor and HD anthracycline | 35.3 (8.30-150.18) | 26.8 (4.34-165.2) | 5.4 (1.53-18.95) | 3.3 (0.82-13.22) |
Case-control matching criteria included: age at HCT (±5 years), year of HCT (±2 years), and duration of follow-up. The model was also adjusted for sex, diagnosis (lymphoma vs nonlymphoma), pre-HCT exposure to chest radiation, and individual pre-HCT comorbidity.